Armatus Bio

Armatus Bio is a privately-held biotechnology innovation company in the late preclinical stage. The company leverages vectorized RNAi to address unmet critical medical needs in gene-driven neurological disorders. Headquartered in Columbus, Ohio, Armatus Bio is led by a team with extensive experience in drug development and delivery and collaborates with world-renowned experts in vector biology, genomics, and neurology. The company’s lead candidate for the treatment of Charcot Marie Tooth Type 1A (CMT1A) has received both "Orphan Drug" and "Rare Pediatric Disease" designations and is currently undergoing IND-enabling studies. Additionally, the company is developing a preclinical vectorized RNAi therapeutic for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a rare neuromuscular disease.